We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
EIP Pharma announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for the cognitive dysfunction associated with Huntington's disease, a rare, genetically inherited disease that causes the nerve cells of ...
EIP Pharma LLC announced today that a 3-month phase 2a clinical trial showed that neflamapimod is a brain-penetrating small molecule that inhibits the intracellular enzyme p38 MAP kinase alpha (p38α)